Drug-loaded bone repair material and its manufacturing method

A titanium-based bone repair material with a nanoporous titanium oxide and calcium titanate layer integrated with a biodegradable polymer membrane addresses adhesion and drug release issues, ensuring stable bone integration and sustained drug delivery for effective bone repair.

JP7587226B2Active Publication Date: 2024-11-20MIE UNIVERSITY +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2020053488
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-03-25
Publication Date
2024-11-20
Estimated Expiration
2040-03-25

AI Technical Summary

Technical Problem

Existing bone repair materials face challenges in achieving high adhesion strength between the base material and polymer membrane, sustained drug release, maintaining the shape integrity, and promoting apatite formation for stable bone integration, particularly in areas of high mechanical stress.

Method used

A bone repair material comprising a titanium-based substrate with a nanoporous titanium oxide and/or calcium titanate layer integrated with a biodegradable polymer membrane, which contains drugs and exhibits scratch resistance, allowing for slow drug release and apatite formation, enhancing bone integration.

Benefits of technology

The material promotes rapid bone integration, supports sustained drug release, and maintains structural integrity, making it effective for bone repair and osteoporosis treatment, especially in load-bearing areas.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587226000004
    Figure 0007587226000004
  • Figure 0007587226000005
    Figure 0007587226000005
  • Figure 0007587226000006
    Figure 0007587226000006
Patent Text Reader

Abstract

To provide a highly safe bone repair material that has high adhesion strength between substrate and polymer membrane, releases drug slowly, hardly changes the shape of the substrate, and has excellent apatite forming ability.SOLUTION: Provided is a bone repair material, characterized, that comprises a substrate made of titanium metal or titanium alloy, a layer of titanium oxide and / or calcium titanate on the surface of the substrate and having a nano-porous structure, a biodegradable polymer membrane such as gelatin integrated with the layer, and a drug such as sodium alendronate or other bisphosphonate contained in and / or adhered to the membrane, and has a scratch resistance of 10 mN or more.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a bone repair material and a manufacturing method thereof. TECHNICAL FIELD This bone repair material can be suitably used for bone repair in areas where a large load is applied, such as the femur, hip joint, spine, tooth root, etc. [Background technology]

[0002] Titanium metal or titanium alloys have high fracture toughness and excellent biocompatibility, and are therefore widely used in the fields of orthopedics and dentistry as bone repair materials in areas where large loads are applied. Anodizing, hydrothermal treatment, and chemical-heating treatment have been proposed as surface treatment methods for forming nanoscale irregularities on the surface of a substrate made of titanium metal or titanium alloy, and all of these have been reported to be effective in improving cell affinity, apatite formation ability, and bone bonding ability (Non-Patent Documents 1-3).

[0003] Anodizing can easily form nanoporous layers or nanotubes on metal surfaces by controlling the voltage, but it is difficult to apply uniform treatment to the inner walls of porous substrates due to the electrostatic shielding effect. Hydrothermal treatment requires special equipment with excellent sealing properties and strength, and tends to grow granular or needle-like crystals, making it difficult to form nanoporous layers. Chemical-heat treatment can easily form nanoporous layers, and can form uniform treatment layers on the inner walls of porous substrates and on surfaces with complex shapes created by 3D modeling technology (Patent Document 1). Furthermore, a treatment method has been proposed in which various functional ions are incorporated into the titanate that constitutes the treatment layer (Patent Document 2).

[0004] On the other hand, bisphosphonates such as minodronic acid and sodium alendronate are heat-resistant and difficult to decompose in vivo, and are mainly used clinically for bone fragility diseases such as osteoporosis, and their effectiveness in increasing bone density has been reported (Non-Patent Documents 4-5). If biological bone is formed around the bone repair material early and an apatite layer is formed on the surface of the material early, strong bonding between the bone repair material and biological bone is obtained early, and it is expected that stable bone bonding can be obtained for a long period of time even in osteoporosis patients. In order to release these drugs gradually, a method of incorporating them into a polymer membrane such as gelatin or collagen and crosslinking them has been proposed (Patent Documents 3-4). In addition, it has been reported that sodium alginate and calcium alginate promote the proliferation of chondrocytes and intervertebral disc cells, but inhibit the adhesion of cells to the surface of the base material (Non-Patent Documents 6 and 7). Therefore, if sodium alginate and calcium alginate can be supported at a certain distance from the bone repair material, their application to artificial intervertebral discs and the like is expected. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] WO2009 / 147819 publication [Patent Document 2] WO2014 / 027612 publication [Patent Document 3] WO2011 / 096402 publication [Patent Document 4] WO2011 / 052089 publication [Non-patent literature]

[0006] [Non-Patent Document 1] Tsutsumi et al., Appl. Surf. Sci., vol.262, p34-38 (2012) [Non-Patent Document 2] Park JW et al., Biomaterials, vol. 28, p3306-3313 (2007) [Non-Patent Document 3] Kokubo et al., J. Am. Ceram. Soc., vol.79, p1127-1129 (1996) [Non-Patent Document 4] Fleisch et al., Endocrine reviews, vol.19, p80-100 (1998) [Non-Patent Document 5] Garcia-Moreno et al., Bone, vol.22, p233-239 (1998) [Non-Patent Document 6] Hauselmann et al., Ame. J. Physiol.-cell Physiol., vol.271, p742-752 (1996) [Non-Patent Document 7] Rawley et al., Biomaterials, vol. 20, p45-53 (1999) Summary of the Invention [Problem to be solved by the invention]

[0007] However, materials obtained only by the processes described in Patent Documents 1 and 2 do not contain, and cannot contain, drugs with large molecular weights. The materials obtained by the methods described in Patent Documents 3 and 4 have a weak adhesive strength between the substrate and the drug-containing polymer film. Therefore, an object of the present invention is to provide a highly safe bone repair material which has high adhesive strength between the substrate and the polymer film, slowly releases a drug, hardly changes the shape of the substrate, and has excellent apatite-forming ability. [Means for solving the problem]

[0008] In order to solve the above problems, the bone repair material of the present invention comprises: The device is characterized by comprising a substrate made of titanium metal or a titanium alloy, a layer of titanium oxide and / or calcium titanate having a nanoporous structure on the surface of the substrate, a biodegradable polymer membrane integrated with the layer, and a drug contained in and / or fixed to the membrane, and by having a scratch resistance of 10 mN or more.

[0009] The shape of the substrate may be any of plate-like, rod-like, cylindrical, solid, mesh, porous, and combinations thereof. When the substrate is in the shape of a mesh, the substrate surface refers to the outer peripheral surface of each wire constituting the mesh, and when the substrate is in the shape of a porous body, the substrate surface refers to the inner peripheral surface of each hole. In this specification, the nanoporous structure refers to a structure having a plurality of nano-sized pores, usually a large number of them. Biodegradability refers to the property of dissolving in the in vivo environment, the property of dissolving in an inorganic solvent such as water, or the property of dissolving due to an organic factor such as an enzyme, and the involvement of microorganisms is not essential. The drug may be any drug that has the effect of suppressing a decrease in bone mass or increasing bone density. In addition, it may be any drug that acts together with calcium ions or phosphate ions to exhibit bone regeneration ability. Scratch resistance refers to the critical scratch strength of the layer when a stylus with a spring constant of 200 g / mm is applied to the layer with an amplitude of 100 μm and moved at a speed of 10 μm / sec while applying a load of 100 mN / min.

[0010] According to this bone repair material, the biodegradable polymer membrane is integrated with the layer and contains and / or is attached to a drug, so that the polymer membrane gradually decomposes in vivo, gradually releasing the drug and promoting bone formation in the surrounding area. The layer gradually releases calcium or phosphate ions, and at the same time exhibits apatite-forming ability, enabling bonding with bone. Even after the polymer membrane is completely decomposed, the poorly soluble titanium oxide or calcium titanate in vivo forms apatite in vivo and bonds with bone, so stable bone bonding can be obtained for a long period of time.

[0011] A suitable method for producing the bone repair material of the present invention comprises a layer formation step of forming a layer of titanium oxide and / or calcium titanate having a nanoporous structure, and a membrane formation step of turning the polymer into a membrane by contacting the layer with a solution containing a biodegradable polymer, characterized in that a drug is either pre-impregnated in the solution or a drug is attached to the polymer after the layer has been contacted with the solution.

[0012] The layer forming step may be composed of the following three partial steps, in which case the solution containing the biodegradable polymer is a fourth aqueous solution described below. The three partial steps include, for example, a partial step of immersing a substrate made of titanium or a titanium alloy in an alkaline first aqueous solution that does not contain calcium ions and contains one or more cations of sodium ions and potassium ions, a partial step of immersing the substrate in a second aqueous solution containing calcium ions, a partial step of heating the substrate in the atmosphere, and a step of immersing the substrate in a third aqueous solution made of warm water and / or an acid aqueous solution.

[0013] By immersing the substrate in the first aqueous solution, the titanium in the substrate reacts with the aqueous solution to form a layer of sodium hydrogen titanate or potassium hydrogen titanate with a nanoporous structure on the substrate surface. By immersing the substrate in the second aqueous solution, the sodium or potassium ions in the sodium hydrogen titanate or potassium hydrogen titanate layer are exchanged for calcium ions in the aqueous solution. By heating the substrate in air, it is dehydrated to form a mechanically and chemically stable anhydrous calcium titanate layer, and the scratch resistance of the surface layer is significantly improved. By immersing the substrate in the third aqueous solution, which is made of warm water or an acid aqueous solution, some of the calcium ions in the titanate layer are exchanged for hydronium ions, and the surface is activated to the extent that it exhibits apatite-forming ability. The apatite-forming ability is so high that it takes seven days to form apatite on the entire surface.

[0014] The layer-forming step may comprise a partial step of contacting a substrate made of titanium or a titanium alloy with an aqueous solution of a strong acid or strong alkali, followed by a partial step of heating, whereby a layer of positively or negatively charged nanoporous titanium oxide is formed on the substrate surface, and activated to the extent that it exhibits apatite-forming ability in the same manner as above. Whether the layer-forming step comprises at least three sub-steps of immersing the substrate in the first to third aqueous solutions or a sub-step of contacting the substrate with a strong acid or strong alkali, the titanium in the layer originates from the substrate, and therefore the substrate and the layer are continuous, and the porosity of the layer increases with increasing distance from the substrate.

[0015] The film formation step usually includes a partial step of contacting the layer with a fourth aqueous solution containing a drug and a biodegradable polymer. This allows the drug and biodegradable polymer to rapidly infiltrate into the nanoporous structure of the layer. The contacting means may be dip coating or spin coating. After contact with the fourth aqueous solution, the layer is dried in air to form a drug-containing polymer film integrated with the layer having a nanoporous structure on the surface of the substrate. The drug is distributed almost uniformly within the film. The thickness of the film can be controlled by adjusting the concentration of the fourth aqueous solution and the conditions of dip coating or spin coating, such as the number of times.

[0016] By adding one or more ions selected from strontium, magnesium, zinc, lithium, gallium, iodine, etc. to the second and third aqueous solutions, a part of the calcium in the calcium titanate can be replaced with these ions. The bone repair material obtained in this way can elute the ions even after all the drug has been eluted, promoting bone formation in the surrounding area and exhibiting antibacterial properties.

[0017] By dividing the membrane formation process into a partial process of contacting the layer with a drug-free biodegradable polymer solution and a partial process of contacting the layer with a drug-containing solution, a drug-free polymer membrane can be formed between the polymer membrane containing drugs such as sodium alginate and calcium alginate and the substrate. The bone repair material thus obtained dissolves drugs such as sodium alginate and calcium alginate at a location appropriately distant from the titanium oxide / calcium titanate layer, promoting the proliferation of chondrocytes and intervertebral disc cells, and the drug does not prevent the cells from adhering to the layer. By strengthening the crosslinking of the polymer membrane integrated with the above layer by chemical crosslinking, thermal crosslinking, or radiation ionization crosslinking, the sustained release performance of the drug can be further improved. Effect of the Invention

[0018] As described above, the bone repair material obtained by this invention, when implanted in a living body, promotes bone formation in the surrounding area and quickly bonds with the living bone to repair bone defects, and is particularly useful for the treatment of osteoporotic bones and the reconstruction of intervertebral discs. [Brief description of the drawings]

[0019] [Figure 1] 4 shows electron microscope photographs of the surface and cross section of the samples of Comparative Example 5 and Examples 1 to 3. [Diagram 2] 1 shows electron microscope photographs of the surfaces of samples of the examples and comparative examples after they were immersed in a simulated body fluid for 7 days. [Diagram 3] 1 shows the time-dependent change in concentration of minodronate monohydrate dissolved in phosphate buffered saline from a sample of an example. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0020] The titanium oxide / calcium titanate layer having a nanoporous structure preferably has a thickness of 0.3 to 10 μm. This thickness range includes the portion where the polymer is mixed with titanium oxide / calcium titanate. If the thickness is less than 0.3 μm, a sufficiently high adhesive strength cannot be obtained between the polymer film. If the thickness exceeds 10 μm, the titanium oxide / calcium titanate layer is likely to peel off from the substrate. The calcium concentration contained in calcium titanate is preferably 0.1 to 10 mass % in terms of imparting apatite forming ability. Usually, the mass % of Ca when the surface is analyzed by EDX at an accelerating voltage of 9 kV corresponds to this concentration.

[0021] The pore size of the nanoporous structure is usually 10-1000 nm. If the pore size is less than 10 nm, the drug and polymer membrane will not easily infiltrate, and if it is greater than 1000 nm, the mechanical strength of the nanoporous structure will decrease. As long as there are pores with a pore size in the above range, pores with a size less than 10 nm may also coexist.

[0022] The concentration of sodium or potassium ions in the first aqueous solution is usually in the range of 1 to 25 M, and the temperature of the aqueous solution is 40 to 95° C., preferably in the range of 5 to 10 M and in the range of 60 to 95° C. If either of these does not reach the lower limit, the reaction for forming sodium hydrogen titanate or potassium hydrogen titanate having a nanoporous structure in the aqueous solution becomes difficult to proceed.

[0023] The calcium ion concentration in the second aqueous solution is usually in the range of 0.01 to 5000 mM, preferably 0.01 to 100 mM. If the concentration is below the lower limit, it becomes difficult to introduce calcium ions at a preferred concentration into the sodium hydrogen titanate or potassium hydrogen titanate. If the concentration exceeds the upper limit, stable compounds that are unfavorable to apatite formation tend to form on the surface.

[0024] The temperature and holding time when the substrate is heated in the atmosphere are usually 400° C. or higher and 0.5 hours or longer, and preferably 600° C. or higher and 1 hour or longer. If either of them does not reach the lower limit, the scratch resistance of the titanium oxide / calcium titanate layer becomes poor.

[0025] When an aqueous solution containing an acid is used as the third aqueous solution, the acid concentration is usually 0.001 to 100 mM, and preferably 0.01 to 100 mM. If the acid concentration is less than the lower limit, only the same effect as when cold water is used is obtained, and if the acid concentration is more than the upper limit, stable compounds that are detrimental to apatite formation are likely to be formed on the surface. The temperature of the third aqueous solution and the immersion time when the substrate is immersed are usually 60° C. or higher and 3 hours or longer, respectively, and preferably 80° C. or higher and 24 hours or longer. When an acid solution is used as the third aqueous solution, activation is achieved in a shorter time and / or at a lower temperature than when water is used. When the immersion temperature and immersion time are below the lower limits, activation is not sufficient.

[0026] The biodegradable polymer contained in the fourth aqueous solution is It is gelatinThe melting point of the fourth aqueous solution is 30 to 95°C. Therefore, by immersing the substrate in the fourth aqueous solution at a temperature equal to or higher than the melting point, the fourth aqueous solution quickly infiltrates the inner walls of the calcium titanate having a nanoporous structure formed on the substrate surface. Thereafter, the temperature of the aqueous solution drops below the melting point of the polymer during drying, causing the polymer to solidify. If the melting point is below the lower limit, the fourth aqueous solution will flow on the substrate surface during drying at room temperature, making it difficult for the polymer to solidify and failing to form a uniform film.

[0027] The drug contained in the fourth aqueous solution is usually one or a combination of two or more selected from bisphosphonates effective for osteoporosis such as minodronic acid and sodium alendronate, alginates such as sodium alginate and calcium alginate, and their derivatives. Furthermore, it is preferable to contain 10 to 5000 mM of either calcium or phosphate ions in this aqueous solution in order to enhance the apatite-forming ability. If either of them is below the lower limit, it is difficult to enhance the apatite-forming ability of the polymer film compared to one that does not contain either of them, and if it exceeds the upper limit, there is a concern that it may exhibit cytotoxicity. In addition, if both are contained, calcium phosphate particles will precipitate in the fourth aqueous solution, making it difficult for the polymer film to exhibit uniform apatite formation.

[0028] In order to enhance the apatite-forming ability, the fourth aqueous solution may contain ions or particles other than calcium and phosphate, such as silica gel, titania gel, niobium oxide gel, zirconia gel, and tantalum oxide gel.

[0029] The thickness of the polymer film is usually 1 to 20 μm, and preferably 1 to 10 μm. This thickness range includes the part where the titanium oxide / calcium titanate is mixed with the polymer. If the thickness is less than the lower limit, a sufficient amount of the drug cannot be supported, and if the thickness exceeds the upper limit, the film is likely to peel off. EXAMPLES

[0030] Example 1 A Ti-6Al-4V alloy plate with a size of 10mm x 10mm x 1mm was polished using a diamond pad of #400, and ultrasonically cleaned with acetone, 2-propanol, and ultrapure water for 30 minutes each, then immersed in 5ml of 5M sodium hydroxide aqueous solution at 95°C for 24 hours and washed with ultrapure water for 30 seconds. This titanium alloy plate was immersed in 10ml of 100mM calcium chloride aqueous solution at 40°C for 24 hours. Next, the alloy plate was heated from room temperature to 600°C at a rate of 5°C / min in an electric furnace, held at 600°C in the air for 1 hour, and cooled in the furnace. After that, it was immersed in 80°C hot water for 24 hours and washed with ultrapure water for 30 seconds (hereinafter referred to as "calcium-heat treatment"). The treated substrate was immersed in a 10 wt% gelatin aqueous solution containing 5 μM sodium alendronate and 100 mM (NH4)2HPO4 at 60°C and withdrawn at a speed of 1 cm / min (hereinafter referred to as "dip coating treatment") to obtain a sample of bone repair material.

[0031] Example 2 Samples were prepared under the same conditions as in Example 1, except that in the dip coating process of Example 1, a 20 wt% gelatin aqueous solution was used instead of a 10 wt% gelatin aqueous solution, and 5 μM minodronate monohydrate and 100 mM CaCl2 were added instead of 5 μM sodium alendronate and 100 mM (NH4)2HPO4.

[0032] Example 3 In the dip coating process of Example 1, the samples were produced under the same conditions as in Example 1, except that they were immersed in a 10 wt % gelatin aqueous solution containing no drugs or additives at 60°C, pulled out at a speed of 5 cm / min, dried at room temperature, and then immersed in a 2 wt % sodium alginate aqueous solution at 60°C and pulled out at a speed of 1 cm / min (hereinafter referred to as "lamination process").

[0033] Example 4 Samples were prepared under the same conditions as in Example 1, except that in the dip coating treatment of Example 1, 50 μM minodronate monohydrate and 15 mM Ca(OH)2 were added instead of 5 μM sodium alendronate and 100 mM (NH4)2HPO4.

[0034] Example 5 A sample was produced under the same conditions as in Example 4, except that after the dip coating treatment, the sample was heated at 140° C. for 3 days in a vacuum of 1 Pa or less (hereinafter referred to as "crosslinking treatment").

[0035] Example 6 A sample was prepared under the same conditions as in Example 4, except that in the dip coating treatment in Example 4, 500 μM minodronate monohydrate was used instead of 50 μM minodronate monohydrate.

[0036] Example 7 The sample was prepared under the same conditions as in Example 4, except that in the dip coating treatment in Example 4, 100 mM CaCl2 was used instead of 15 mM Ca(OH)2.

[0037] Example 8 A sample was produced under the same conditions as in Example 7, except that after the dip coating treatment in Example 7, a crosslinking treatment was carried out.

[0038] Example 9 A sample was produced under the same conditions as in Example 8, except that a round bar of the same quality as the alloy plate and measuring 2.5 mm in diameter and 10 mm in length was used instead of the alloy plate.

[0039] -Comparative Example 1- In the dip coating treatment of Example 1, a sample was prepared under the same conditions as in Example 1, except that a gelatin aqueous solution containing 100 mM CaCl2 and 100 mM (NH4)2HPO4 was used instead of 5 μM sodium alendronate and 100 mM (NH4)2HPO4. -Comparative Example 2- An alloy plate of the same shape and quality as that of Example 1 was diamond-polished in the same manner as in Example 1, then ultrasonically cleaned in acetone, propanol, and ultrapure water in that order, and then immersed in 50% diluted aqua regia at 40°C for 1 hour, then immersed in 10 wt% gelatin aqueous solution at 60°C, and pulled up at a speed of 1 cm / min to produce a sample. This example corresponds to Patent Document 3.

[0040] --Comparative Example 3-- In the calcium-heat treatment of Example 1, the heat treatment and hot water treatment were not performed (hereinafter referred to as "calcium treatment"), and no chemicals or additives were added in the dip coating treatment. Except for this, samples were produced under the same conditions as in Example 1. --Comparative Example 4-- A sample was produced under the same conditions as in Example 9, except that the dip coating treatment was not carried out. --Comparative Example 5-- A sample was produced under the same conditions as in Example 1, except that the dip coating treatment was not carried out.

[0041] The manufacturing conditions for the samples of the above examples and comparative examples are shown in Table 1. [Table 1]

[0042] [Electron microscope observation] When the cross sections of the sample of Comparative Example 5 and the samples of Examples 1-3 were observed under an electron microscope at an accelerating voltage of 15 kV, it was found that gelatin had infiltrated into the inner walls of the calcium titanate layer, which had a nanoporous structure with pores of 10-800 nm, as shown in Figure 1, and that the calcium titanate layer and the gelatin film were integrated into one structure. Since the thickness of the gelatin film was about 1.8 μm in Example 1 and about 4.0 μm in Examples 2 and 3, it was found that the thickness could be controlled by adjusting the gelatin concentration and the pulling speed in the dip coating process. Furthermore, by performing a lamination process after the dip coating process, sodium alginate could be supported about 1.5 μm above the top end of the calcium titanate layer through the gelatin film, as seen in Example 3.

[0043] [Apatite formation ability evaluation] When the samples of the Examples and Comparative Examples were immersed in simulated body fluid (SBF) of ISO Standard 23317 maintained at 36.5°C, apatite precipitated covering the entire surface, i.e., 99% or more of the total surface area, in all Examples within 7 days of SBF immersion, as shown in Figure 2 and Table 2. Therefore, it was confirmed that these samples exhibit high apatite forming ability in vivo. On the other hand, the sample of Comparative Example 1, which was dip-coated with the fourth aqueous solution containing both calcium ions and phosphate ions, formed apatite only on less than 50% of the total surface area even after 7 days of SBF immersion.

[0044] [Table 2]

[0045] [Scratch resistance rating] The scratch resistance of the samples of the examples and the samples of comparative examples 1-3 was measured using a scratch tester. As shown in Table 2, the scratch resistance of the samples of the examples was high, at 50 mN or more, while both comparative examples 2 and 3 showed scratch resistance of only 10 mN or less.

[0046] [Evaluation of drug dissolution] The samples of Examples 4, 5, 7, and 8 were immersed in phosphate buffered saline (PBS) maintained at 36.5°C for various periods of time, and the concentration of calcium ions dissolved in each solution was measured using an ICP emission spectrometer. Since the calcium ions were uniformly contained in the gelatin membrane together with the drug, it was found that the amount of calcium ions dissolved in PBS with the dissolution of the gelatin membrane was strongly correlated with the amount of drug dissolved. Therefore, the concentration of minodronate monohydrate was calculated from the calcium ion concentration.

[0047] The results are shown in Figure 3. In the figure, the horizontal axis scale indicates the square root of the immersion time (hours) at the top and the immersion time (days) at the bottom. As shown in the figure, Example 4 dissolved 0.85 μM of minodronate monohydrate within 1 hour, and further released 0.1 μM by 7 days. Example 5, which was crosslinked, significantly suppressed the initial dissolution and increased the amount of subsequent sustained release. Similar effects of the crosslinking treatment were observed in Examples 7 and 8.

[0048] [Evaluation of pull-out breaking strength] The samples of Example 9 and Comparative Example 4 were embedded in the spines of beagles, and the pull-out breaking strength was measured when they were pulled out after 12 or 24 weeks. As shown in Table 3, the sample of Example 9 showed a significantly stronger pull-out breaking strength than the sample of Comparative Example 4 at 12 weeks.

[0049] [Table 3]

Claims

1. The present invention comprises a substrate made of titanium metal or a titanium alloy, a layer of titanium oxide and / or calcium titanate having a nanoporous structure on the surface of the substrate, a biodegradable polymer film made of gelatin having a melting point of 30-95°C integrated with the layer, and a drug contained and / or fixed to the film; A drug-loaded bone repair material, characterized in that the layer and the polymer membrane are integrated by the infiltration of the polymer in the polymer membrane into the layer, and the layer has a scratch resistance of 10 mN or more.

2. The bone repair material of claim 1, wherein the nanoporous structure has pores with a diameter of 10-1000 nm.

3. 2. The bone repair material of claim 1, wherein a portion of the calcium in the calcium titanate layer is replaced with one or more ions selected from sodium, potassium, strontium, magnesium, zinc, lithium, iodine and gallium ions.

4. The bone repair material of claim 1, wherein the layer has a thickness of 0.3 to 10 μm.

5. The bone repair material of claim 1, wherein the polymer membrane has a thickness of 1 to 20 μm.

6. The bone repair material according to claim 1 , wherein the drug is one or a combination of two or more selected from the group consisting of bisphosphonates, and alginates and their derivatives.

7. The bone repair material of claim 6 , wherein the bisphosphonate is minodronic acid or sodium alendronate.

8. The bone repair material according to claim 1 , wherein the titanium in the titanium oxide and / or calcium titanate originates from the titanium in the base material.

9. The bone repair material of claim 1 , wherein the drug is uniformly contained in the polymer film.

10. The bone repair material of claim 1 , wherein the drug is affixed to a surface of the polymer membrane remote from the substrate.

11. The method comprises a layer forming step of forming a layer of titanium oxide and / or calcium titanate having a nanoporous structure on the surface of a substrate made of titanium or a titanium alloy, and a film forming step of contacting the layer with an aqueous solution containing a biodegradable polymer made of gelatin having a melting point of 30-95°C, and infiltrating the polymer in the polymer film into the layer, thereby forming the polymer into a film; A method for producing a drug-loaded bone repair material, comprising: preliminarily adding a drug to the solution; or contacting the layer with the solution and then attaching the drug to the polymer.

12. 12. The manufacturing method according to claim 11, wherein the layer forming step comprises a partial step of immersing the substrate in an alkaline first aqueous solution containing no calcium ions and at least one cation selected from the group consisting of sodium ions and potassium ions, a partial step of immersing the substrate in a second aqueous solution containing calcium ions, a partial step of heating the substrate in the atmosphere, and a partial step of immersing the substrate in a third aqueous solution consisting of hot water or an acid aqueous solution.

13. The method of claim 12, wherein the second and third aqueous solutions contain one or more ions selected from ions of strontium, magnesium, zinc, lithium, gallium, iodine, and the like.

14. The method according to claim 11 , wherein the film-forming step includes a sub-step of dip-coating the layer together with the substrate in an aqueous solution containing the polymer, or a sub-step of spin-coating the layer.

15. The method according to claim 14 , wherein the film forming step includes a partial step of dip coating or spin coating, and the partial step is repeated.

16. The method according to claim 11, wherein the aqueous solution containing the biodegradable polymer further contains 10 to 5000 mM calcium ions or phosphate ions.

17. The method according to claim 11 , further comprising a crosslinking step of chemically crosslinking, thermally crosslinking, or radiation ionization crosslinking the polymer formed into a film.

Citation Information

Patent Citations

  • Bone repair material and method for producing the same

    JP2017144342A

  • Compositions and products for use in treating fractures and bone defects

    JP2017522373A

  • Bone-repairing material and method for producing the same

    WO2009147819A1

  • Carrier materials for in vivo sustained release of drug comprising ionizing radiation-crosslinked hydrogel and method for producing same

    WO2011052089A1

  • Biocompatible device

    WO2011096402A1